HETANG Venture Capital
荷塘创投基金
HETANG Venture Capital (荷塘创投) is a Chinese venture capital fund with a focus on healthcare and deep-tech investments. Per BlueRun Ventures reporting, it led the Series A round in CAS-Ruiyi (中科睿医), a neurological disease intelligent diagnosis startup, in February 2023 , and participated again in the company's Series A+ round by December 2024 . It also co-invested in Inming Biotech's (炎明生物) RMB 700 million Series A in autumn 2023 alongside state-backed investors like SDIC Venture Capital and China Life .
The fund appears to operate as an institutional LP-backed vehicle — its name appears as "荷塘创投基金" (HETANG Venture Capital Fund) in deal announcements — though elsewhere's corpus does not cover its founding date, AUM, or full team composition.
AI-generated — may contain errors, please verify.
Coverage
CereMediTech Successfully Completes Series A+ Funding Round | BlueRun Ventures
Building the "New Infrastructure" for Diagnosing and Treating Neurological Disorders
Autumn's Prime: Six FreeS Fund Early-Stage Portfolio Companies Raise Nearly 1 Billion RMB | FreeS Family Funding News Vol.15
Looking forward to working alongside more outstanding founders.
CereMediTech Completes Tens of Millions of Yuan in Series A Funding to Advance Intelligent Diagnosis and Treatment Infrastructure for Neurological Diseases | BlueRun Ventures
Intelligent Technology Solutions for Full-Spectrum Neurological Diseases
